Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05645302

Intensive Monitoring Scheme of Lidocaine Cataplasms

Conditions: Adverse Reaction to Drug

Sex: All
Enrollment: 200
Sponsor: Qianfoshan Hospital

Location: China

Summary

In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).

Eligibility Criteria

Inclusion Criteria:All patients receiving Lidocaine Cataplasms from January 1, 2021 to April 1, 2022.Exclusion Criteria:Unable to obtain complete medication information.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05645302). StuddyBuddy aggregates publicly available trial information.